Navigation Links
Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008
Date:4/21/2008

etive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care.

Quest Diagnostics maintains the largest private clinical laboratory data warehouse in the United States. The data is used to generate Quest Diagnostics Health Trends(TM), which identifies and tracks disease and wellness benchmarks, and the Drug Testing Index(R), which is published as a public service for government, media and industry and has been considered a benchmark for national drugs-of-abuse trends since its inception in 1988. Additional company information is available at http://www.questdiagnostics.com.

About Quest Diagnostics' Campaign to Challenge Colorectal Cancer

Quest Diagnostics recently launched a new education campaign aimed at breaking down barriers to compliance with tests used to screen for colorectal cancer. The goal of the new campaign is to have five million people complete their annual testing over the next five years. The Challenge urges individuals to talk to their healthcare providers about annual colorectal cancer screening using the InSure(R) FIT(TM) take-home test. Medical experts advise that anyone at age 50 or older at average risk should, as one of their screening options, be screened annually with an FOBT or FIT for this disease. To learn more about the Challenge and InSure FIT, please visit http://www.DoYouHaveTheGuts.com.

The statements in this press release which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve ri
'/>"/>

SOURCE Quest Diagnostics Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Vioxx Disclosure Emphasizes Need for New Web Resource that Answers Questions About Anti-Epileptic Medication Use
2. Susan G. Komen for the Cure Advocacy Alliance Suggests Questions for Tonights Presidential Debate
3. ImQuest Presents New Anti-HIV Drug and Topical Microbicide Development Results on Lead Pyrimidinedione Products IQP-0410 and IQP-0528
4. Quest Diagnostics to Release First Quarter 2008 Financial Results and Conduct Quarterly Investor Conference Call
5. New conference tackles the tough questions in lung cancer
6. The Quest for Americas Life in Beautiful Smiles: Captured in Photography
7. SurgiQuest Announces First Procedure Using AirSeal(TM) Access System
8. Study questions cost of complexity in evolution
9. Conseco Declines Partnerships Request for Board Seats; Review of Strategic Alternatives Underway
10. Large Disparities in Kidney Testing Based on Disease, Gender and State, Quest Diagnostics Health Trends(TM) Report Finds
11. Use of Methamphetamine Among U.S. Workers and Job Applicants Drops 22 Percent in 2007 and Cocaine Use Slows Dramatically, Reports Quest Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3RetireSafe Announces Intention to Key Vote Senator Dorgan's Drug Importation Amendment (SA 2793) 2Hand Surgeons Take Ethics into Their Own Hands 2Hand Surgeons Take Ethics into Their Own Hands 3Hand Surgeons Take Ethics into Their Own Hands 411 More Children Die From Swine Flu 3A CDC 59676 111 More Children Die From Swine Flu 3A CDC 59676 211 More Children Die From Swine Flu 3A CDC 59676 3President Barack Obama Joins President George H W Bush to Celebrate the 20th Anniversary of the Points of Light Volunteer Movement and Extend the Cal 59671 1President Barack Obama Joins President George H W Bush to Celebrate the 20th Anniversary of the Points of Light Volunteer Movement and Extend the Cal 59671 2President Barack Obama Joins President George H W Bush to Celebrate the 20th Anniversary of the Points of Light Volunteer Movement and Extend the Cal 59671 3President Barack Obama Joins President George H W Bush to Celebrate the 20th Anniversary of the Points of Light Volunteer Movement and Extend the Cal 59671 4President Barack Obama Joins President George H W Bush to Celebrate the 20th Anniversary of the Points of Light Volunteer Movement and Extend the Cal 59671 5President Barack Obama Joins President George H W Bush to Celebrate the 20th Anniversary of the Points of Light Volunteer Movement and Extend the Cal 59671 6Peregrine Pharmaceuticals Announces Implementation of 1 3A5 Reverse Stock Split to Take Effect October 19 2009 59666 1Peregrine Pharmaceuticals Announces Implementation of 1 3A5 Reverse Stock Split to Take Effect October 19 2009 59666 2Peregrine Pharmaceuticals Announces Implementation of 1 3A5 Reverse Stock Split to Take Effect October 19 2009 59666 3Peregrine Pharmaceuticals Announces Implementation of 1 3A5 Reverse Stock Split to Take Effect October 19 2009 59666 4
Other Medicine Technology:Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 2Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 3Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 4Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 5Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 6Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 2Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 3Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 4Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 5Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 6Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 7